DNA Methylation and the Increased Risk of Cervical Cancer Development

Launched by ZHUJIANG HOSPITAL · Mar 4, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how certain bacteria in the reproductive system and changes in DNA may be linked to the risk of developing cervical cancer. Researchers are looking to see if these factors can help explain why some women with human papillomavirus (HPV) or abnormal Pap test results might be more likely to develop cervical cancer. The study will involve women between the ages of 18 and 50 who have had recent HPV and Pap tests done at a gynecology clinic.

To participate, women must have a history of sexual activity and be willing to undergo additional testing if their HPV or Pap test results are abnormal. Unfortunately, pregnant or breastfeeding women, as well as those with certain health conditions or recent treatments, won't be eligible for this trial. If you join the study, you will provide samples for testing, and the researchers will monitor how these factors relate to cervical cancer risk. This is a valuable opportunity to contribute to important research that could help improve women’s health in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged 18-50 years old, with a history of sexual activity
• • 2. HPV and TCT tests are performed concurrently in the gynecology clinic
• • 3. Those with abnormal HPV and TCT test results undergo tissue pathological testing
• Exclusion Criteria:
• • 1. Pregnant or breastfeeding
• • 2. Patients with immunological disorders or severe autoimmune diseases, such as AIDS, SLE
• • 3. Those who have had organ transplants or are currently using immunosuppressive agents
• • 4. Use of vaginal douching within 48 hours before sample collection
• • 5. Use of vaginal probiotics within one month before sample collection
• • 6. Use of vaginal antibiotics or antifungal treatments within one month before sample collection
• • 7. History of surgery related to cervical intraepithelial neoplasia (CIN), including but not limited to conization of the cervix, LEEP procedures, etc.
• • 8. Blood samples (avoid sampling during menstruation), insufficient remaining sample volume to support subsequent analysis needs, and samples not stored as required.